Loading...

Fran Aweeka, PharmD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentClinical Pharmacy
Address1001 Potrero Ave, SFGH 100
San Francisco CA 94110
Phone415-476-0339
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Southern CaliforniaB.S. Biological Sciences1981
    University of California, San FranciscoPharm.D.1985 Pharmacy
    University of California, San FranciscoPHA Primary Practice Residency1986 Pharmacy
    University of California, San FranciscoPharmacology Fellowship1988

    Collapse Research 
    Collapse Research Activities and Funding
    Pharmacodynamics of Antimalarial Chemoprevention
    NIH/NIAID R01AI117001Feb 10, 2015 - Jan 31, 2020
    Role: Principal Investigator
    Antimalarial Pharmacology in HIV Coinfected Children and Pregnant Women in Uganda
    NIH R01HD068174Dec 23, 2010 - Aug 31, 2021
    Role: Principal Investigator
    UCSF-Gladstone Center for AIDS Research
    NIH/NIAID P30AI027763Sep 30, 1988 - Aug 31, 2022
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT. Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. PLoS One. 2018; 13(8):e0202082. PMID: 30114201.
      View in: PubMed
    2. Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, Aweeka F, Kiechel JR, Jullien V, Rijken MJ, McGready R, Mwesigwa J, Kristensen K, Stepniewska K, Tarning J, Barnes KI, Denti P. Population Pharmacokinetics of the Antimalarial Amodiaquine: A Pooled Analysis to Optimize Dosing. Antimicrob Agents Chemother. 2018 Jul 23. PMID: 30038039.
      View in: PubMed
    3. Jagannathan P, Kakuru A, Okiring J, Muhindo MK, Natureeba P, Nakalembe M, Opira B, Olwoch P, Nankya F, Ssewanyana I, Tetteh K, Drakeley C, Beeson J, Reiling L, Clark TD, Rodriguez-Barraquer I, Greenhouse B, Wallender E, Aweeka F, Prahl M, Charlebois ED, Feeney ME, Havlir DV, Kamya MR, Dorsey G. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med. 2018 Jul; 15(7):e1002606. PMID: 30016328.
      View in: PubMed
    4. Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018 Jun; 15(6):e1002579. PMID: 29894518.
      View in: PubMed
    5. Glennon EKK, Megawati D, Torrevillas BK, Ssewanyana I, Huang L, Aweeka F, Greenhouse B, Adams LG, Luckhart S. Elevated plasma abscisic acid is associated with asymptomatic falciparum malaria and with IgG-/caspase-1-dependent immunity in Plasmodium yoelii-infected mice. Sci Rep. 2018 Jun 11; 8(1):8896. PMID: 29891920.
      View in: PubMed
    6. Huang L, Haagensen JAJ, Verotta D, Cheah V, Spormann AM, Aweeka F, Yang K. Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid. J Anal Methods Chem. 2018; 2018:7965124. PMID: 29854560.
      View in: PubMed
    7. Ippolito MM, Huang L, Siame M, Thuma P, Shapiro TA, Aweeka FT. Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS. J Pharm Biomed Anal. 2018 Jun 05; 155:241-246. PMID: 29655094.
      View in: PubMed
    8. Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT. Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis. 2018 Mar 14. PMID: 29547881.
      View in: PubMed
    9. Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM. Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis. 2018 Mar 05; 217(6):964-972. PMID: 29272443.
      View in: PubMed
    10. Jagannathan P, Kajubi R, Aweeka FT. Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction". Clin Pharmacol Ther. 2018 Apr; 103(4):571. PMID: 29322501.
      View in: PubMed
    11. Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ. Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. J Infect Dis. 2017 Nov 15; 216(8):1008-1017. PMID: 28968782.
      View in: PubMed
    12. Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. PLoS One. 2017; 12(10):e0186589. PMID: 29065172.
      View in: PubMed
    13. Ivaturi V, Dvorak CC, Chan D, Liu T, Cowan MJ, Wahlstrom J, Stricherz M, Jennissen C, Orchard PJ, Tolar J, Pai SY, Huang L, Aweeka F, Long-Boyle J. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2017 Oct; 23(10):1701-1713. PMID: 28684371.
      View in: PubMed
    14. O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA. A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infect Dis. 2017; 4(1):ofw278. PMID: 28480270.
      View in: PubMed
    15. Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S. Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infect Dis. 2016 Oct; 3(4):ofw217. PMID: 28018925.
      View in: PubMed
    16. Tchaparian E, Sambol NC, Arinaitwe E, McCormack SA, Bigira V, Wanzira H, Muhindo M, Creek DJ, Sukumar N, Blessborn D, Tappero JW, Kakuru A, Bergqvist Y, Aweeka FT, Parikh S. Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. J Infect Dis. 2016 Oct 15; 214(8):1243-51. PMID: 27471317; PMCID: PMC5034953.
    17. Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis. 2016 Aug 01; 63(3):414-22. PMID: 27143666.
      View in: PubMed
    18. Jagannathan P, Bowen K, Nankya F, McIntyre TI, Auma A, Wamala S, Sikyomu E, Naluwu K, Nalubega M, Boyle MJ, Farrington LA, Bigira V, Kapisi J, Aweeka F, Greenhouse B, Kamya M, Dorsey G, Feeney ME. Effective Antimalarial Chemoprevention in Childhood Enhances the Quality of CD4+ T Cells and Limits Their Production of Immunoregulatory Interleukin 10. J Infect Dis. 2016 Jul 15; 214(2):329-38. PMID: 27067196; PMCID: PMC4918829 [Available on 07/15/17].
    19. Weinberg A, Park JG, Bosch R, Cho A, Livingston E, Aweeka F, Cramer Y, Watts DH, Luque AE, Cohn SE. Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):137-45. PMID: 26413850; PMCID: PMC4712075 [Available on 02/01/17].
    20. Dumond JB, Rigdon J, Mollan K, Tierney C, Kashuba AD, Aweeka F, Collier AC. Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results. J Acquir Immune Defic Syndr. 2015 Dec 15; 70(5):510-4. PMID: 26230332; PMCID: PMC4648657 [Available on 12/15/16].
    21. Nyunt MM, Nguyen VK, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Mwima MW, Achan J, Aweeka F, Parikh S, Mwebaza N. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1274-82. PMID: 26666942; PMCID: PMC4775973.
    22. Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Malar J. 2015 Sep 24; 14:368. PMID: 26403465; PMCID: PMC4582734.
    23. Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. Antimicrob Agents Chemother. 2015 Dec; 59(12):7852-6. PMID: 26392500; PMCID: PMC4649208.
    24. Sha BE, Tierney C, Sun X, Stek A, Cohn SE, Coombs RW, Bastow B, Aweeka FT. PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150. Jacobs J AIDS HIV. 2015; 1(1). PMID: 26878071.
      View in: PubMed
    25. Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 06 15; 60(12):1842-51. PMID: 25767256.
      View in: PubMed
    26. Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Pediatr Infect Dis J. 2015 Mar; 34(3):e63-70. PMID: 25742090; PMCID: PMC4351793.
    27. Luque AE, Cohn SE, Park JG, Cramer Y, Weinberg A, Livingston E, Klingman KL, Aweeka F, Watts DH. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study. Antimicrob Agents Chemother. 2015 Apr; 59(4):2094-101. PMID: 25624326; PMCID: PMC4356823.
    28. Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 01; 67(4):375-81. PMID: 25162818.
      View in: PubMed
    29. Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28; 28(18):2701-9. PMID: 25493596; PMCID: PMC4487368.
    30. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71. PMID: 25285539.
      View in: PubMed
    31. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014 Aug; 11(8):e1001689. PMID: 25093754; PMCID: PMC4122345.
    32. Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep; 58(9):5245-52. PMID: 24957823; PMCID: PMC4135849.
    33. Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. Determination of meropenem in bacterial media by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15; 961:71-6. PMID: 24861874; PMCID: PMC4104812.
    34. Huang L, Lizak P, Dvorak CC, Aweeka F, Long-Boyle J. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 01; 960:194-9. PMID: 24820973; PMCID: PMC4110960.
    35. Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka OO, Parikh S. Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. J Antimicrob Chemother. 2014 May; 69(5):1370-6. PMID: 24446424; PMCID: PMC3977609.
    36. Kjellin LL, Dorsey G, Rosenthal PJ, Aweeka F, Huang L. Determination of the antimalarial drug piperaquine in small volume pediatric plasma samples by LC-MS/MS. Bioanalysis. 2014; 6(23):3081-9. PMID: 25529877; PMCID: PMC4321809.
    37. Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F. Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol. 2014 Feb; 54(2):121-32. PMID: 24038035; PMCID: PMC3933454.
    38. Huang L, Lizak P, Aweeka F, Long-Boyle J. Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS. J Pharm Biomed Anal. 2013 Dec; 86:198-203. PMID: 24013121; PMCID: PMC3835489.
    39. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):578-84. PMID: 24135775; PMCID: PMC3800282.
    40. Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF. Interactions between alcohol and the HIV entry inhibitor Maraviroc. J Int Assoc Provid AIDS Care. 2013 Nov-Dec; 12(6):375-7. PMID: 23881910; PMCID: PMC4100473.
    41. Huang L, Olson A, Gingrich D, Aweeka FT. Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method. Bioanalysis. 2013 Jun; 5(12):1501-6. PMID: 23795928; PMCID: PMC3879143.
    42. Liu L, Wang L, Huang L, Siu V, Teque F, Aweeka FT, Levy JA. Nevirapine inhibits the anti-HIV activity of CD8+ cells. J Acquir Immune Defic Syndr. 2013 Jun 01; 63(2):184-8. PMID: 23392464; PMCID: PMC3653990.
    43. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. PMID: 23592830; PMCID: PMC3719885.
    44. Gwaza L, Aweeka F, Greenblatt R, Lizak P, Huang L, Guglielmo BJ. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis. 2013 Oct; 17(10):e857-61. PMID: 23587599; PMCID: PMC3776002.
    45. Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013 Jun; 57(6):2780-7. PMID: 23571542; PMCID: PMC3716161.
    46. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis. 2013 Jun 01; 207(11):1646-54. PMID: 23447696.
      View in: PubMed
    47. Jain V, Liegler T, Kabami J, Chamie G, Clark TD, Black D, Geng EH, Kwarisiima D, Wong JK, Abdel-Mohsen M, Sonawane N, Aweeka FT, Thirumurthy H, Petersen ML, Charlebois ED, Kamya MR, Havlir DV. Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis. 2013 Feb; 56(4):598-605. PMID: 23243180; PMCID: PMC3552523.
    48. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, Charlebois E, Aweeka F, Dorsey G, Rosenthal PJ, Havlir D, Kamya MR. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012 Nov 29; 367(22):2110-8. PMID: 23190222; PMCID: PMC3664297.
    49. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):310-6. PMID: 22918158; PMCID: PMC3511816.
    50. Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012 Oct; 56(10):5374-80. PMID: 22869579; PMCID: PMC3457371.
    51. Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica. 2012 Nov; 42(11):1088-95. PMID: 22671777.
      View in: PubMed
    52. Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, Sawe F, Currier JS, Lockman S, Aweeka FT. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012 Apr 24; 26(7):833-41. PMID: 22301417; PMCID: PMC3506024.
    53. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012 Apr 15; 59(5):455-62. PMID: 22126739; PMCID: PMC3302922.
    54. Fehintola FA, Scarsi KK, Ma Q, Parikh S, Morse GD, Taiwo B, Akinola IT, Adewole IF, Lindegardh N, Phakderaj A, Ojengbede O, Murphy RL, Akinyinka OO, Aweeka FT. Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults. AIDS Res Treat. 2012; 2012:703604. PMID: 22500218; PMCID: PMC3303559.
    55. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012 Jan; 4(2):157-66. PMID: 22250798; PMCID: PMC3321395.
    56. Sha BE, Tierney C, Cohn SE, Sun X, Coombs RW, Frenkel LM, Kalams SA, Aweeka FT, Bastow B, Bardeguez A, Kmack A, Stek A. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials. 2011 Jan-Feb; 12(1):9-23. PMID: 21388937; PMCID: PMC3227722.
    57. Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010 Dec; 55(4):473-82. PMID: 20842042; PMCID: PMC4197050.
    58. Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):361-4. PMID: 20595906; PMCID: PMC3164483.
    59. Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):285-9. PMID: 19890215; PMCID: PMC3119357.
    60. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, Barbour JD, Lowe MM, Jayawardene A, Aweeka F, Huang Y, Douek DC, Brenchley JM, Martin JN, Hecht FM, Deeks SG, McCune JM. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med. 2010 May 19; 2(32):32ra36. PMID: 20484731; PMCID: PMC3034445.
    61. Huang L, Lizak PS, Jayewardene AL, Marzan F, Lee MN, Aweeka FT. A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. Anal Chem Insights. 2010 Mar 29; 5:15-23. PMID: 20448843; PMCID: PMC2865164.
    62. Pao VY, Lee GA, Taylor S, Aweeka FT, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers. AIDS. 2010 Jan 16; 24(2):265-70. PMID: 19890203.
      View in: PubMed
    63. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, Clark TD, Dorsey G, Lindegardh N, Annerberg A, Rosenthal PJ, Kamya MR, Aweeka F. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010 Jan; 54(1):52-9. PMID: 19841149; PMCID: PMC2798532.
    64. Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One. 2009 Sep 01; 4(9):e6877. PMID: 19721718; PMCID: PMC2731205.
    65. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009 Aug 01; 51(4):424-9. PMID: 19506482.
      View in: PubMed
    66. Huang L, Jayewardene AL, Li X, Marzan F, Lizak PS, Aweeka FT. Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma. J Pharm Biomed Anal. 2009 Dec 05; 50(5):959-65. PMID: 19646837; PMCID: PMC3034030.
    67. Eron JJ, Park JG, Haubrich R, Aweeka F, Bastow B, Pakes GE, Yu S, Wu H, Richman DD. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009 Jun; 53(6):2335-41. PMID: 19307363; PMCID: PMC2687257.
    68. Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15; 877(3):285-90. PMID: 19112051; PMCID: PMC3032609.
    69. Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008 Aug 01; 47(3):421-4. PMID: 18558886; PMCID: PMC2586907.
    70. Venhoff N, Venhoff AC, Jayewardene AL, Aweeka F, Lebrecht D, Walker UA. Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX. J Acquir Immune Defic Syndr. 2008 May 01; 48(1):114-6. PMID: 18438180.
      View in: PubMed
    71. German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 2008; 47(2):91-102. PMID: 18193915.
      View in: PubMed
    72. Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, Schambelan M, Grunfeld C. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. AIDS. 2007 Oct 18; 21(16):2183-90. PMID: 18090045; PMCID: PMC3167072.
    73. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 Oct 18; 21(16):2191-9. PMID: 18090046.
      View in: PubMed
    74. German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, Lindegardh N, Havlir D, Aweeka FT. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007 Mar 15; 44(6):889-91. PMID: 17304470.
      View in: PubMed
    75. Aweeka FT, Rosenkranz SL, Segal Y, Coombs RW, Bardeguez A, Thevanayagam L, Lizak P, Aberg J, Watts DH. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS. 2006 Sep 11; 20(14):1833-41. PMID: 16954724.
      View in: PubMed
    76. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006 Sep 01; 43(5):658-60. PMID: 16886163; PMCID: PMC3205942.
    77. McGee B, Smith N, Aweeka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials. 2006 May-Jun; 7(3):142-53. PMID: 16880170.
      View in: PubMed
    78. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 01; 192(9):1537-44. PMID: 16206068.
      View in: PubMed
    79. Jacobson MA, Nicolau DP, Sutherland C, Smith A, Aweeka F. Pharmacokinetics of clarithromycin extended-release (ER) tablets in patients with AIDS. HIV Clin Trials. 2005 Sep-Oct; 6(5):246-53. PMID: 16306031.
      View in: PubMed
    80. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11. PMID: 15498605.
      View in: PubMed
    81. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, Mulligan K, Schambelan M, Grunfeld C. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004 Mar 05; 18(4):641-9. PMID: 15090769; PMCID: PMC3166345.
    82. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004; 44:499-523. PMID: 14744256.
      View in: PubMed
    83. Soy D, Aweeka FT, Church JA, Cunningham CK, Palumbo P, Kosel BW, Sheiner LB. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther. 2003 Dec; 74(6):569-80. PMID: 14663459.
      View in: PubMed
    84. Floren LC, Wiznia A, Hayashi S, Jayewardene A, Stanley K, Johnson G, Nachman S, Krogstad P, Aweeka FT. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003 Sep; 112(3 Pt 1):e220-7. PMID: 12949316.
      View in: PubMed
    85. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003 Aug 19; 139(4):258-66. PMID: 12965981.
      View in: PubMed
    86. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003 May 23; 17(8):1195-9. PMID: 12819521.
      View in: PubMed
    87. Chi J, Jayewardene AL, Stone JA, Aweeka FT. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. J Pharm Biomed Anal. 2003 Apr 01; 31(5):953-9. PMID: 12684107.
      View in: PubMed
    88. Chi J, Jayewardene AL, Stone JA, Motoya T, Aweeka FT. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. J Pharm Biomed Anal. 2002 Oct 15; 30(3):675-84. PMID: 12367693.
      View in: PubMed
    89. Wohl DA, Aweeka FT, Schmitz J, Pomerantz R, Cherng DW, Spritzler J, Fox L, Simpson D, Bell D, Holohan MK, Thomas S, Robinson W, Kaplan G, Teppler H. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis. 2002 May 01; 185(9):1359-63. PMID: 12001058.
      View in: PubMed
    90. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002 Mar 29; 16(5):F1-8. PMID: 11964551; PMCID: PMC3166537.
    91. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Blaschke T, Alston B, Fang F, Kosel B, Aweeka F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002 Mar 08; 16(4):569-77. PMID: 11873000.
      View in: PubMed
    92. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, Abrams DI. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS. 2002 Mar 08; 16(4):543-50. PMID: 11872997.
      View in: PubMed
    93. Herforth C, Stone JA, Jayewardene AL, Blaschke TF, Fang F, Motoya T, Aweeka FT. Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization. Eur J Pharm Sci. 2002 Mar; 15(2):185-95. PMID: 11849916.
      View in: PubMed
    Fran's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _